EA201170191A1 - Антагонисты phk, нацеленные на gli2 - Google Patents

Антагонисты phk, нацеленные на gli2

Info

Publication number
EA201170191A1
EA201170191A1 EA201170191A EA201170191A EA201170191A1 EA 201170191 A1 EA201170191 A1 EA 201170191A1 EA 201170191 A EA201170191 A EA 201170191A EA 201170191 A EA201170191 A EA 201170191A EA 201170191 A1 EA201170191 A1 EA 201170191A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gli2
phk
antagonists aimed
antagonists
aimed
Prior art date
Application number
EA201170191A
Other languages
English (en)
Inventor
Май Хедтьерн
Original Assignee
Сантарис Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантарис Фарма А/С filed Critical Сантарис Фарма А/С
Publication of EA201170191A1 publication Critical patent/EA201170191A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к олигомерным соединениям (олигомерам), которые нацелены на мРНК GLI2 в клетке, вызывая пониженную экспрессию GLI2. Снижение экспрессии GLI2 является благоприятным фактором для лечения определенных медицинских нарушений, в частности гиперпролиферативных нарушений, таких как рак.
EA201170191A 2008-07-15 2009-07-15 Антагонисты phk, нацеленные на gli2 EA201170191A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08104754 2008-07-15
US8113508P 2008-07-16 2008-07-16
PCT/IB2009/006407 WO2010007522A1 (en) 2008-07-15 2009-07-15 Rna antagonists targeting gli2

Publications (1)

Publication Number Publication Date
EA201170191A1 true EA201170191A1 (ru) 2011-08-30

Family

ID=41100628

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170191A EA201170191A1 (ru) 2008-07-15 2009-07-15 Антагонисты phk, нацеленные на gli2

Country Status (12)

Country Link
US (1) US20110124709A1 (ru)
EP (1) EP2310506A1 (ru)
JP (1) JP2011527901A (ru)
KR (1) KR20110031976A (ru)
CN (1) CN102159712A (ru)
AU (1) AU2009272365A1 (ru)
CA (1) CA2730641A1 (ru)
EA (1) EA201170191A1 (ru)
IL (1) IL210650A0 (ru)
MX (1) MX2011000601A (ru)
TW (1) TW201016222A (ru)
WO (1) WO2010007522A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201102073A (en) 2009-07-15 2011-01-16 Enzon Pharmaceuticals Inc RNA antagonists targeting GLI2 for the treatment of leukemia
JP6336755B2 (ja) 2010-11-12 2018-06-06 ザ ジェネラル ホスピタル コーポレイション ポリコームに関連する非コードｒｎａ
JP2015518714A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド 遺伝子発現を調節するための組成物及び方法
CA2873779A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating mecp2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
US20220275374A1 (en) * 2019-11-14 2022-09-01 The Board Of Regents Of The University Of Oklahoma Oligonucleotide interference treatments of prostate cancer
CN110923234A (zh) * 2019-12-20 2020-03-27 广东药科大学 一种抑制人GLI2基因表达的shRNA构建及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440739B1 (en) * 2001-07-17 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-2 expression

Also Published As

Publication number Publication date
TW201016222A (en) 2010-05-01
KR20110031976A (ko) 2011-03-29
CA2730641A1 (en) 2010-01-21
AU2009272365A1 (en) 2010-01-21
WO2010007522A1 (en) 2010-01-21
CN102159712A (zh) 2011-08-17
US20110124709A1 (en) 2011-05-26
MX2011000601A (es) 2011-03-01
WO2010007522A8 (en) 2010-03-04
EP2310506A1 (en) 2011-04-20
IL210650A0 (en) 2011-03-31
JP2011527901A (ja) 2011-11-10

Similar Documents

Publication Publication Date Title
EA201170191A1 (ru) Антагонисты phk, нацеленные на gli2
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
EA201390381A1 (ru) Триазиноксадиазолы
EA201171367A1 (ru) Винилиндазолильные соединения
EA201070660A1 (ru) Lna-антагонисты андрогенного рецептора
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
EA201070670A1 (ru) Являющиеся антагонистами рнк соединения для модуляции экспрессии pik3ca
MY166026A (en) Tetrahydro-pyrido-pyrimidine derivatives
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
EA201391106A1 (ru) Новые гетероциклические производные
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
MX347241B (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX2013005751A (es) Quinazolincarboxamida azetidinas.
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek
MX346095B (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
MX349548B (es) Compuestos de tienopirimidina.
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку